Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
15 May 2021
Historique:
received: 20 09 2020
accepted: 05 05 2021
entrez: 16 5 2021
pubmed: 17 5 2021
medline: 6 11 2021
Statut: epublish

Résumé

Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality and its incidence is increasing in many countries despite management guidelines. A national quality improvement programme called the Obstetric Bleeding Strategy for Wales (OBS Cymru) was introduced in all obstetric units in Wales. The aim was to reduce moderate PPH (1000 mL) progressing to massive PPH (> 2500 mL) and the need for red cell transfusion. A PPH care bundle was introduced into all 12 obstetric units in Wales included all women giving birth in 2017 and 2018 (n = 61,094). The care bundle prompted: universal risk assessment, quantitative measurement of blood loss after all deliveries (as opposed to visual estimation), structured escalation to senior clinicians and point-of-care viscoelastometric-guided early fibrinogen replacement. Data were submitted by each obstetric unit to a national database. Outcome measures were incidence of massive PPH (> 2500 mL) and red cell transfusion. Analysis was performed using linear regression of the all Wales monthly data. Uptake of the intervention was good: quantitative blood loss measurement and risk assessment increased to 98.1 and 64.5% of all PPH > 1000 mL, whilst ROTEM use for PPH > 1500 mL increased to 68.2%. Massive PPH decreased by 1.10 (95% CI 0.28 to 1.92) per 1000 maternities per year (P = 0.011). Fewer women progressed from moderate to massive PPH in the last 6 months, 74/1490 (5.0%), than in the first 6 months, 97/1386 (7.0%), (P = 0.021). Units of red cells transfused decreased by 7.4 (95% CI 1.6 to 13.2) per 1000 maternities per year (P = 0.015). Red cells were transfused to 350/15204 (2.3%) and 268/15150 (1.8%) (P = 0.001) in the first and last 6 months, respectively. There was no increase in the number of women with lowest haemoglobin below 80 g/L during this time period. Infusions of fresh frozen plasma fell and there was no increase in the number of women with haemostatic impairment. The OBS Cymru care bundle was feasible to implement and associated with progressive, clinically significant improvements in outcomes for PPH across Wales. It is applicable across obstetric units of widely varying size, complexity and staff mixes.

Sections du résumé

BACKGROUND BACKGROUND
Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality and its incidence is increasing in many countries despite management guidelines. A national quality improvement programme called the Obstetric Bleeding Strategy for Wales (OBS Cymru) was introduced in all obstetric units in Wales. The aim was to reduce moderate PPH (1000 mL) progressing to massive PPH (> 2500 mL) and the need for red cell transfusion.
METHODS METHODS
A PPH care bundle was introduced into all 12 obstetric units in Wales included all women giving birth in 2017 and 2018 (n = 61,094). The care bundle prompted: universal risk assessment, quantitative measurement of blood loss after all deliveries (as opposed to visual estimation), structured escalation to senior clinicians and point-of-care viscoelastometric-guided early fibrinogen replacement. Data were submitted by each obstetric unit to a national database. Outcome measures were incidence of massive PPH (> 2500 mL) and red cell transfusion. Analysis was performed using linear regression of the all Wales monthly data.
RESULTS RESULTS
Uptake of the intervention was good: quantitative blood loss measurement and risk assessment increased to 98.1 and 64.5% of all PPH > 1000 mL, whilst ROTEM use for PPH > 1500 mL increased to 68.2%. Massive PPH decreased by 1.10 (95% CI 0.28 to 1.92) per 1000 maternities per year (P = 0.011). Fewer women progressed from moderate to massive PPH in the last 6 months, 74/1490 (5.0%), than in the first 6 months, 97/1386 (7.0%), (P = 0.021). Units of red cells transfused decreased by 7.4 (95% CI 1.6 to 13.2) per 1000 maternities per year (P = 0.015). Red cells were transfused to 350/15204 (2.3%) and 268/15150 (1.8%) (P = 0.001) in the first and last 6 months, respectively. There was no increase in the number of women with lowest haemoglobin below 80 g/L during this time period. Infusions of fresh frozen plasma fell and there was no increase in the number of women with haemostatic impairment.
CONCLUSIONS CONCLUSIONS
The OBS Cymru care bundle was feasible to implement and associated with progressive, clinically significant improvements in outcomes for PPH across Wales. It is applicable across obstetric units of widely varying size, complexity and staff mixes.

Identifiants

pubmed: 33992094
doi: 10.1186/s12884-021-03853-y
pii: 10.1186/s12884-021-03853-y
pmc: PMC8126150
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

377

Subventions

Organisme : Welsh Government
ID : NA

Références

Am J Obstet Gynecol. 2017 Mar;216(3):298.e1-298.e11
pubmed: 28153661
Br J Haematol. 2018 Sep;182(6):789-806
pubmed: 30073664
J Matern Fetal Neonatal Med. 2020 May 4;:1-7
pubmed: 32366138
Int J Gynaecol Obstet. 2006 Jun;93(3):220-4
pubmed: 16626718
BMJ Open Qual. 2020 Apr;9(2):
pubmed: 32273281
BMC Pregnancy Childbirth. 2015 Sep 28;15:230
pubmed: 26415952
Risk Manag Healthc Policy. 2017 Jan 17;10:1-6
pubmed: 28176919
Br J Haematol. 2014 Jan;164(2):177-88
pubmed: 24383841
Am J Perinatol. 2013 Jan;30(1):1-4
pubmed: 22836824
Br J Anaesth. 2017 Sep 1;119(3):411-421
pubmed: 28969312
Arch Gynecol Obstet. 2018 Dec;298(6):1071-1077
pubmed: 30225686
BJOG. 2006 Aug;113(8):919-24
pubmed: 16907938
Curr Opin Anaesthesiol. 2016 Apr;29(2):212-9
pubmed: 26705132
Am J Obstet Gynecol. 2015 Mar;212(3):272-80
pubmed: 25025944
Int J Obstet Anesth. 2015 Feb;24(1):8-14
pubmed: 25433576
J Thromb Haemost. 2016 Jan;14(1):205-10
pubmed: 27028301
Blood. 2015 Apr 30;125(18):2759-70
pubmed: 25769619
Am J Surg. 2009 May;197(5):565-70; discussion 570
pubmed: 19393349
Anaesthesia. 2016 Jun;71(6):648-56
pubmed: 27062151
Am J Obstet Gynecol. 2011 Oct;205(4):368.e1-8
pubmed: 22083059
Anaesthesia. 2015 Jan;70 Suppl 1:78-86, e27-8
pubmed: 25440400
Am J Obstet Gynecol. 2008 Nov;199(5):519.e1-7
pubmed: 18639209
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Lancet. 2017 May 27;389(10084):2105-2116
pubmed: 28456509
Anesth Analg. 1995 Aug;81(2):360-5
pubmed: 7542432
Eur J Obstet Gynecol Reprod Biol. 1991 Jan 30;38(2):119-24
pubmed: 1995380
J Obstet Gynecol Neonatal Nurs. 2018 Sep;47(5):707-718
pubmed: 29940149
Acta Obstet Gynecol Scand. 2011 Jun;90(6):615-20
pubmed: 21370999
J Thromb Haemost. 2007 Feb;5(2):266-73
pubmed: 17087729
Am J Obstet Gynecol. 2013 Nov;209(5):449.e1-7
pubmed: 23871950
BMC Pregnancy Childbirth. 2020 May 6;20(1):271
pubmed: 32375687
Int J Obstet Anesth. 2012 Jan;21(1):79-83
pubmed: 22119633
Int J Obstet Anesth. 2011 Apr;20(2):135-41
pubmed: 21439811
Anaesthesia. 2019 Aug;74(8):984-991
pubmed: 30950521
Blood. 2014 Sep 11;124(11):1727-36
pubmed: 25024304
Taiwan J Obstet Gynecol. 2017 Dec;56(6):715-718
pubmed: 29241907
Br J Anaesth. 2017 Sep 1;119(3):422-434
pubmed: 28969328
Int J Obstet Anesth. 2019 Feb;37:106-117
pubmed: 30322667

Auteurs

Sarah F Bell (SF)

Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.

Rachel E Collis (RE)

Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.

Philip Pallmann (P)

Deputy Director Research Design and Conduct Centre, Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.

Christopher Bailey (C)

Department of Anaesthetics, Intensive Care and Pain Medicine, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Bodelwyddan, UK.

Kathryn James (K)

Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.

Miriam John (M)

Department of Emergency Medicine, Aneurin Bevan University Health Board, Newport, UK.

Kevin Kelly (K)

Department of Anaesthetics, Intensive Care and Pain Medicine, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Bodelwyddan, UK.

Thomas Kitchen (T)

Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.

Cerys Scarr (C)

Department of Obstetrics and Gynaecology, Cardiff and Vale University Health Board, Cardiff, UK.

Adam Watkins (A)

Improvement Cymru, Public Health Wales, Cardiff, UK.

Tracey Edey (T)

Department of Midwifery, Singleton Hospital, Swansea, UK.

Elinore Macgillivray (E)

Improvement Cymru, Public Health Wales, Cardiff, UK.

Kathryn Greaves (K)

Department of Obstetrics and Gynaecology, Cwm Taf Morgannwg Health Board, Merthyr Tydfil, UK.

Ingrid Volikas (I)

Department of Anaesthetics, Intensive Care and Pain Medicine, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Bodelwyddan, UK.

James Tozer (J)

Department of Anaesthetics and Intensive Care, Aneurin Bevan University Health Board, Newport, UK.

Niladri Sengupta (N)

Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Bodelwyddan, UK.

Iolo Roberts (I)

Department of Anaesthetics, Intensive Care and Pain Medicine, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Bodelwyddan, UK.

Claire Francis (C)

Department of Obstetrics and Gynaecology, Cardiff and Vale University Health Board, Cardiff, UK.

Peter W Collins (PW)

Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK. Peter.collins@wales.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH